SCHEMBL3450291

SCHEMBL3450291

CCOC(=O)c1cncc(-c2cnc(Nc3cccc(F)c3)nc2-n2ccc(C(F)(F)F)n2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 3/20 0.50
HTT P42858 2/20 0.42
MAPK1 P28482 1/20 0.42
LCK P06239 1/20 0.42
BTK Q06187 1/20 0.42
SIRT5 Q9NXA8 1/20 0.41
TYK2 P29597 3/20 0.39
JAK1 P23458 2/20 0.39
JAK2 O60674 1/20 0.39
JAK3 P52333 1/20 0.39
FGFR1 P11362 2/20 0.39
KDM4E B2RXH2 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
CNR2 P34972 1/20 0.38
KDR P35968 1/20 0.38
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3451287 0.93 SYK (0.51) SYKSIRT5TYK2JAK1JAK2
SCHEMBL3449331 0.93 SYK (0.44) SYKTYK2JAK1JAK2JAK3
SCHEMBL3450518 0.92 SYK (0.49) SYKSIRT5TYK2JAK1JAK2
SCHEMBL3448083 0.92 SYK (0.51) SYKTYK2JAK1JAK2JAK3
SCHEMBL3450247 0.91 SYK (0.51) SYKHTTTYK2JAK1JAK2
SCHEMBL3449839 0.91 SYK (0.43) SYKTYK2JAK1JAK2JAK3
SCHEMBL3449544 0.91 SYK (0.48) SYKTYK2JAK1JAK2JAK3
SCHEMBL13311923 0.90 SYK (0.48) SYKTYK2JAK1JAK2JAK3
SCHEMBL3448893 0.90 SYK (0.48) SYKTYK2JAK1JAK2JAK3
SCHEMBL3448166 0.89 SYK (0.45) SYKTYK2JAK1JAK2JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF SDHA, SDHB, UROD SYK 804/4885HTT 3861/4885MAPK1 2905/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.